Drug Patents Expiring in 2032
1. Abilify Mycite Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10517507 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jun, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: NA
Dosage: TABLET;ORAL
ABILIFY MYCITE KIT family patents
2. Abraxane patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9393318 | BRISTOL-MYERS | Methods of treating cancer |
Mar, 2032
(7 years from now) | |
| US9597409 | BRISTOL-MYERS | Methods of treating cancer |
Mar, 2032
(7 years from now) | |
|
US9393318 (Pediatric) | BRISTOL-MYERS | Methods of treating cancer |
Sep, 2032
(8 years from now) | |
|
US9597409 (Pediatric) | BRISTOL-MYERS | Methods of treating cancer |
Sep, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jun 06, 2023 |
| M(M-14) | Dec 06, 2022 |
| New Indication(I-676) | Sep 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Sep 06, 2020 |
| Orphan Drug Exclusivity(ODE-52) | Sep 06, 2020 |
| New Indication(I-658) | Oct 11, 2015 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: Treatment of lung cancer
Dosage: POWDER;INTRAVENOUS
ABRAXANE family patents
3. Acetadote patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8722738 | CUMBERLAND PHARMS | Acetycysteine compositions and methods of use thereof |
Apr, 2032
(7 years from now) | |
Drugs and Companies using ACETYLCYSTEINE ingredient
Market Authorisation Date: 23 January, 2004
Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions
Dosage: INJECTABLE;INTRAVENOUS
ACETADOTE family patents
4. Adlyxin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9511193 | SANOFI-AVENTIS US | Assembly and indicator for a drug delivery device |
Jan, 2032
(7 years from now) | |
| US9440029 | SANOFI-AVENTIS US | Drive mechanism for a drug delivery device and drug delivery device |
Jan, 2032
(7 years from now) | |
| US9072836 | SANOFI-AVENTIS US | Drive mechanism for a drug delivery device and drug delivery device |
Mar, 2032
(7 years from now) | |
| US9821032 | SANOFI-AVENTIS US | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
May, 2032
(8 years from now) | |
| US9408893 | SANOFI-AVENTIS US | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 27 July, 2016
Treatment: Combination treatment with insulin glargine with or without metformin for improvement of glycemic control in type 2 diabetes mellitus patients; Combination treatment with a glitazone for improvement o...
Dosage: SOLUTION;SUBCUTANEOUS
ADLYXIN family patents
5. Adzenys Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8709491 | NEOS THERAPS INC | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(8 years from now) | |
| US9265737 | NEOS THERAPS INC | Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles |
Jun, 2032
(8 years from now) | |
| US9017731 | NEOS THERAPS INC | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(8 years from now) | |
Drugs and Companies using AMPHETAMINE ingredient
Market Authorisation Date: 15 September, 2017
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
ADZENYS ER family patents
6. Adzenys Xr-odt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8709491 | NEOS THERAPS | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(8 years from now) | |
| US9265737 | NEOS THERAPS | Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles |
Jun, 2032
(8 years from now) | |
| US9017731 | NEOS THERAPS | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(8 years from now) | |
Drugs and Companies using AMPHETAMINE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
ADZENYS XR-ODT family patents
7. Afrezza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8499757 | MANNKIND | Dry powder inhaler and system for drug delivery |
Feb, 2032
(7 years from now) | |
| US8636001 | MANNKIND | Dry powder inhaler and system for drug delivery |
Jul, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 27, 2017 |
Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient
Market Authorisation Date: 27 June, 2014
Treatment: NA
Dosage: POWDER;INHALATION
AFREZZA family patents
8. Airduo Digihaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
| US8978966 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jan, 2032
(7 years from now) | |
| US8714149 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Feb, 2032
(7 years from now) | |
|
US10561808 (Pediatric) | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jul, 2032
(8 years from now) | |
|
US8978966 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jul, 2032
(8 years from now) | |
|
US8714149 (Pediatric) | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
| New Product(NP) | Jan 27, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER;INHALATION
AIRDUO DIGIHALER family patents
9. Airduo Respiclick patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
| US8978966 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jan, 2032
(7 years from now) | |
| US8714149 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Feb, 2032
(7 years from now) | |
|
US10561808 (Pediatric) | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jul, 2032
(8 years from now) | |
|
US8978966 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jul, 2032
(8 years from now) | |
|
US8714149 (Pediatric) | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
| New Product(NP) | Jan 27, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER;INHALATION
AIRDUO RESPICLICK family patents
10. Akynzeo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9403772 | HELSINN HLTHCARE | 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator |
May, 2032
(8 years from now) | |
| US8426450 | HELSINN HLTHCARE | Substituted 4-phenyl pyridines having anti-emetic effect |
May, 2032
(8 years from now) | |
| US11312698 | HELSINN HLTHCARE | Fosnetupitant chloride hydrochloride having improved stability |
May, 2032
(8 years from now) | |
| US9908907 | HELSINN HLTHCARE | Substituted piperaziniums for the treatment of emesis |
May, 2032
(8 years from now) | |
| US10717721 | HELSINN HLTHCARE | Substituted piperaziniums for the treatment of emesis |
May, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895586 | HELSINN HLTHCARE | Methods of treating emesis |
May, 2032
(8 years from now) | |
| US10208073 | HELSINN HLTHCARE | Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator |
May, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 19, 2023 |
NCE-1 date: 19 April, 2022
Market Authorisation Date: 19 April, 2018
Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
AKYNZEO family patents
11. Alecensa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9365514 | HOFFMANN-LA ROCHE | Composition comprising tetracyclic compound |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-159) | Nov 06, 2024 |
| New Indication(I-756) | Nov 06, 2020 |
| Orphan Drug Exclusivity(ODE-105) | Dec 11, 2022 |
| Orphan Drug Exclusivity(ODE) | Nov 06, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 11, 2020 |
Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient
NCE-1 date: 12 December, 2019
Market Authorisation Date: 11 December, 2015
Treatment: NA
Dosage: CAPSULE;ORAL
ALECENSA family patents
12. Aliqopa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10383876 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
Mar, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9636344 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-155) | Sep 14, 2024 |
| Orphan Drug Exclusivity(ODE) | Sep 14, 2024 |
| New Chemical Entity Exclusivity(NCE) | Sep 14, 2022 |
Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient
NCE-1 date: 14 September, 2021
Market Authorisation Date: 14 September, 2017
Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies
Dosage: POWDER;INTRAVENOUS
ALIQOPA family patents
13. Alkindi Sprinkle patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9717740 | ETON | Treatment of adrenal insufficiency |
Nov, 2032
(8 years from now) | |
Drugs and Companies using HYDROCORTISONE ingredient
Market Authorisation Date: 29 September, 2020
Treatment: Treatment of adrenal insufficiency
Dosage: GRANULE;ORAL
ALKINDI SPRINKLE family patents
14. Amvuttra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10570391 | ALNYLAM PHARMS INC | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(8 years from now) | |
| US9399775 | ALNYLAM PHARMS INC | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 13, 2027 |
| Orphan Drug Exclusivity(ODE-212) | Jun 13, 2029 |
Drugs and Companies using VUTRISIRAN SODIUM ingredient
NCE-1 date: 13 June, 2026
Market Authorisation Date: 13 June, 2022
Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
Dosage: SOLUTION;SUBCUTANEOUS
AMVUTTRA family patents
15. Aptiom patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9750747 | SUMITOMO PHARMA AM | Treatments involving eslicarbazepine acetate or eslicarbazepine |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-150) | Aug 27, 2018 |
| New Indication(I-715) | Aug 27, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2018 |
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
NCE-1 date: 08 November, 2017
Market Authorisation Date: 08 November, 2013
Treatment: Treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures
Dosage: TABLET;ORAL
APTIOM family patents
16. Aristada patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10226458 | ALKERMES INC | Pharmaceutical compositions comprising sorbitan esters |
Mar, 2032
(7 years from now) | |
| US9034867 | ALKERMES INC | Pharmaceutical compositions comprising sorbitan esters |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2020 |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
NCE-1 date: 06 October, 2019
Market Authorisation Date: 05 October, 2015
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARISTADA family patents
17. Armonair Digihaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
| US8978966 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jan, 2032
(7 years from now) | |
| US8714149 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Feb, 2032
(7 years from now) | |
|
US10561808 (Pediatric) | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jul, 2032
(8 years from now) | |
|
US8978966 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jul, 2032
(8 years from now) | |
|
US8714149 (Pediatric) | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 09, 2024 |
| New Strength(NS) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
| New Product(NP) | Jan 27, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER;INHALATION
ARMONAIR DIGIHALER family patents
18. Armonair Respiclick patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
| US8978966 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jan, 2032
(7 years from now) | |
| US8714149 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Feb, 2032
(7 years from now) | |
|
US10561808 (Pediatric) | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jul, 2032
(8 years from now) | |
|
US8978966 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jul, 2032
(8 years from now) | |
|
US8714149 (Pediatric) | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 09, 2024 |
| New Strength(NS) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
| New Product(NP) | Jan 27, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER;INHALATION
ARMONAIR RESPICLICK family patents
19. Avycaz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9695122 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(8 years from now) | |
| US8969566 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(8 years from now) | |
| US9284314 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2020 |
| New Patient Population(NPP) | Dec 20, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Feb 25, 2025 |
| New Indication(I-738) | Jun 22, 2019 |
Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient
NCE-1 date: 26 February, 2024
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: POWDER;INTRAVENOUS
AVYCAZ family patents
20. Azstarys patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9079928 | COMMAVE THERAP | Methylphenidate-oxoacid conjugates, processes of making and using the same |
Jul, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 07, 2026 |
NCE-1 date: 07 May, 2025
Market Authorisation Date: 07 May, 2021
Treatment: NA
Dosage: CAPSULE;ORAL
AZSTARYS family patents
21. Belbuca patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9901539 | BDSI | Transmucosal drug delivery devices for use in chronic pain relief |
Dec, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 23, 2018 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 October, 2015
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: FILM;BUCCAL
BELBUCA family patents
22. Belviq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9169213 | EISAI INC | Method of weight management |
Dec, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient
NCE-1 date: 27 June, 2016
Market Authorisation Date: 27 June, 2012
Treatment: Use of belviq (lorcaserin hydrochloride) for chronic weight management by treating obesity in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week...
Dosage: TABLET;ORAL
BELVIQ family patents
23. Belviq Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9169213 | EISAI INC | Method of weight management |
Dec, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient
NCE-1 date: 27 June, 2016
Market Authorisation Date: 15 July, 2016
Treatment: Use of lorcaserin hydrochloride for chronic weight management by treating obesity in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week 12 of tr...
Dosage: TABLET, EXTENDED RELEASE;ORAL
BELVIQ XR family patents
24. Bijuva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10639375 | MAYNE PHARMA | Progesterone formulations |
Nov, 2032
(8 years from now) | |
| US11103516 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US8993549 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US11103513 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US8993548 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US9114146 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US8633178 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US11793819 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US9114145 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US9006222 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US8846648 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US9301920 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US8987237 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US10206932 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US11033626 | MAYNE PHARMA | Progesterone formulations having a desirable pk profile |
Nov, 2032
(8 years from now) | |
| US8846649 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US11529360 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US10052386 | MAYNE PHARMA | Progesterone formulations |
Nov, 2032
(8 years from now) | |
| US8933059 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US11166963 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US10806740 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US11110099 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US10675288 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 28, 2021 |
Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient
Market Authorisation Date: 28 December, 2021
Treatment: Treatment of menopause symptoms, including vasomotor symptoms
Dosage: CAPSULE;ORAL
BIJUVA family patents
25. Biktarvy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-256) | Jun 18, 2026 |
| M(M-82) | Feb 24, 2024 |
| Orphan Drug Exclusivity(ODE-468) | Feb 23, 2031 |
| Orphan Drug Exclusivity(ODE-378) | Oct 07, 2028 |
| New Chemical Entity Exclusivity(NCE) | Feb 07, 2023 |
| New Patient Population(NPP) | Jun 18, 2022 |
NCE-1 date: 07 February, 2022
Market Authorisation Date: 07 October, 2021
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
BIKTARVY family patents
26. Bortezomib patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8962572 | FRESENIUS KABI USA | Bortezomib formulations |
Nov, 2032
(8 years from now) | |
Drugs and Companies using BORTEZOMIB ingredient
Market Authorisation Date: 06 November, 2017
Treatment: NA
Dosage: POWDER;INTRAVENOUS
BORTEZOMIB family patents
27. Braftovi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9763941 | ARRAY BIOPHARMA INC | Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
Nov, 2032
(8 years from now) | |
| US10258622 | ARRAY BIOPHARMA INC | Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate |
Nov, 2032
(8 years from now) | |
| US9387208 | ARRAY BIOPHARMA INC | Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-194) | Jun 27, 2025 |
| New Indication(I-928) | Oct 11, 2026 |
| Orphan Drug Exclusivity(ODE-445) | Oct 11, 2030 |
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2023 |
| New Indication(I-826) | Apr 08, 2023 |
Drugs and Companies using ENCORAFENIB ingredient
NCE-1 date: 27 June, 2022
Market Authorisation Date: 27 June, 2018
Treatment: Treatment of melanoma; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, a...
Dosage: CAPSULE;ORAL
BRAFTOVI family patents
28. Brenzavvy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8987323 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
May, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 20, 2028 |
Drugs and Companies using BEXAGLIFLOZIN ingredient
NCE-1 date: 20 January, 2027
Market Authorisation Date: 20 January, 2023
Treatment: NA
Dosage: TABLET;ORAL
BRENZAVVY family patents
29. Brixadi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9937164 | BRAEBURN | Opioid formulations |
Jul, 2032
(8 years from now) | |
| US11110084 | BRAEBURN | Opioid formulations |
Jul, 2032
(8 years from now) | |
| US11135215 | BRAEBURN | Opioid formulations |
Jul, 2032
(8 years from now) | |
| US10912772 | BRAEBURN | Opioid formulations |
Jul, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 23, 2026 |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 23 May, 2023
Treatment: A method of sustained delivery of buprenorphine to a human or non-human animal body. a method for treatment for opioid maintenance therapy; A method of administering an opioid maintenance treatment co...
Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS
BRIXADI family patents
30. Bunavail patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8703177 | BDSI | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 06, 2017 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 06 June, 2014
Treatment: NA
Dosage: FILM;BUCCAL
BUNAVAIL family patents
31. Cabometyx patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11298349 | EXELIXIS INC | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-227) | Jan 14, 2026 |
| New Indication(I-854) | Jan 22, 2024 |
| Orphan Drug Exclusivity(ODE-375) | Sep 17, 2028 |
| New Indication(I-873) | Sep 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
| New Indication(I-760) | Dec 19, 2020 |
| New Product(NP) | Apr 25, 2019 |
| New Indication(I-792) | Jan 14, 2022 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 25 April, 2016
Treatment: NA
Dosage: TABLET;ORAL
CABOMETYX family patents
32. Caldolor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9072661 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(7 years from now) | |
| US11806400 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(7 years from now) | |
| US9072710 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-128) | Nov 19, 2024 |
| New Patient Population(NPP) | May 11, 2026 |
| New Product(NP) | Jun 11, 2012 |
| New Dosing Schedule(D-152) | Nov 20, 2018 |
Drugs and Companies using IBUPROFEN ingredient
Market Authorisation Date: 11 June, 2009
Treatment: Methods of treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition; Methods of making aqueous composition and treating pain, inflammation, fever, patent ductus ateriosis ...
Dosage: SOLUTION;INTRAVENOUS
CALDOLOR family patents
33. Calquence patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9290504 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9758524 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(8 years from now) | |
| US10239883 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
Jul, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-175) | Oct 31, 2024 |
| Orphan Drug Exclusivity(ODE-274) | Nov 21, 2026 |
| New Indication(I-817) | Nov 21, 2022 |
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2022 |
Drugs and Companies using ACALABRUTINIB ingredient
NCE-1 date: 31 October, 2021
Market Authorisation Date: 31 October, 2017
Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with chronic lymphocytic leukemia
Dosage: CAPSULE;ORAL
CALQUENCE family patents
34. Calquence patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9290504 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9758524 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(8 years from now) | |
| US10239883 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
Jul, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2022 |
Drugs and Companies using ACALABRUTINIB MALEATE ingredient
NCE-1 date: 31 October, 2021
Market Authorisation Date: 03 August, 2022
Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination wi...
Dosage: TABLET;ORAL
CALQUENCE family patents
35. Caspofungin Acetate patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9636407 | FRESENIUS KABI USA | Caspofungin acetate formulations |
Dec, 2032
(8 years from now) | |
Drugs and Companies using CASPOFUNGIN ACETATE ingredient
Market Authorisation Date: 30 December, 2016
Treatment: NA
Dosage: POWDER;INTRAVENOUS
CASPOFUNGIN ACETATE family patents
36. Cetylev patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9427421 | ARBOR PHARMS LLC | Effervescent compositions containing N-acetylcysteine |
May, 2032
(8 years from now) | |
| US9561204 | ARBOR PHARMS LLC | Effervescent compositions containing N-acetylcysteine |
May, 2032
(8 years from now) | |
| US8747894 | ARBOR PHARMS LLC | Effervescent compositions containing N-acetylcysteine |
May, 2032
(8 years from now) | |
Drugs and Companies using ACETYLCYSTEINE ingredient
Market Authorisation Date: 29 January, 2016
Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions
Dosage: TABLET, EFFERVESCENT;ORAL
CETYLEV family patents
37. Cometriq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11298349 | EXELIXIS | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(7 years from now) | |
| US9717720 | EXELIXIS | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-33) | Nov 29, 2019 |
| Orphan Drug Exclusivity(ODE) | Nov 29, 2019 |
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 29 November, 2012
Treatment: NA
Dosage: CAPSULE;ORAL
COMETRIQ family patents
38. Contrave patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9248123 | NALPROPION | Methods of providing weight loss therapy in patients with major depression |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Sep 10, 2017 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: Use of naltrexone and bupropion for chronic weight management for treating overweight or obesity in patients with major depressive disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
CONTRAVE family patents
39. Copiktra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46621 | SECURA | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
May, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11312718 | SECURA | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
Jan, 2032
(7 years from now) | |
| US9840505 | SECURA | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-208) | Sep 24, 2025 |
| Orphan Drug Exclusivity(ODE-209) | Sep 24, 2025 |
| New Chemical Entity Exclusivity(NCE) | Sep 24, 2023 |
Drugs and Companies using DUVELISIB ingredient
NCE-1 date: 24 September, 2022
Market Authorisation Date: 24 September, 2018
Treatment: For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)
Dosage: CAPSULE;ORAL
COPIKTRA family patents
40. Cotempla Xr-odt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9072680 | NEOS THERAPS INC | Compositions comprising methylphenidate complexed with ion-exchange resin particles |
Jun, 2032
(8 years from now) | |
| US9089496 | NEOS THERAPS INC | Compositions comprising methylphenidate complexed with ion-exchange resin particles |
Jun, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 19, 2020 |
Drugs and Companies using METHYLPHENIDATE ingredient
Market Authorisation Date: 19 June, 2017
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
COTEMPLA XR-ODT family patents
41. Cycloset patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9700555 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US10688094 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US8613947 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US11000522 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US8431155 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US9993474 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US9522117 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US9192576 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 05, 2012 |
Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient
Market Authorisation Date: 05 May, 2009
Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 7...
Dosage: TABLET;ORAL
CYCLOSET family patents
42. Daybue patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9212204 | ACADIA PHARMS INC | Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-425) | Mar 10, 2030 |
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2028 |
Drugs and Companies using TROFINETIDE ingredient
NCE-1 date: 11 March, 2027
Market Authorisation Date: 10 March, 2023
Treatment: Treatment of rett syndrome or a symptom thereof
Dosage: SOLUTION;ORAL
DAYBUE family patents
43. Defitelio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11236328 | JAZZ PHARMS INC | Euglobulin-based method for determining the biological activity of defibrotide |
Jun, 2032
(8 years from now) | |
| US11746348 | JAZZ PHARMS INC | Euglobulin-based method for determining the biological activity of defibrotide |
Jun, 2032
(8 years from now) | |
| US11085043 | JAZZ PHARMS INC | Euglobulin-based method for determining the biological activity of defibrotide |
Jun, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-112) | Mar 30, 2023 |
| Orphan Drug Exclusivity(ODE) | Mar 30, 2023 |
| New Chemical Entity Exclusivity(NCE) | Mar 30, 2021 |
Drugs and Companies using DEFIBROTIDE SODIUM ingredient
NCE-1 date: 30 March, 2020
Market Authorisation Date: 30 March, 2016
Treatment: Treatment of adult and pediatric patients with hepatic veno-occlusive disease (vod), also known as sinusoidal obstruction syndrome (sos), with renal or pulmonary dysfunction following hematopoietic st...
Dosage: SOLUTION;INTRAVENOUS
DEFITELIO family patents
44. Descovy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-285) | Sep 28, 2024 |
| Orphan Drug Exclusivity(ODE-284) | Sep 28, 2024 |
| Orphan Drug Exclusivity(ODE-457) | Jan 07, 2029 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Patient Population(NPP) | Sep 28, 2020 |
| New Indication(I-812) | Oct 03, 2022 |
Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient
NCE-1 date: 06 November, 2019
Market Authorisation Date: 07 January, 2022
Treatment: Treatment of hiv-1 infection
Dosage: TABLET;ORAL
DESCOVY family patents
45. Detectnet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10159759 | RADIOMEDIX | Pet tracer for imaging of neuroendocrine tumors |
Aug, 2032
(8 years from now) | |
| US10383961 | RADIOMEDIX | PET tracer for imaging of neuroendocrine tumors |
Aug, 2032
(8 years from now) | |
| US11160888 | RADIOMEDIX | PET tracer for imaging of neuroendocrine tumors |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 03, 2025 |
| Orphan Drug Exclusivity(ODE-317) | Sep 03, 2027 |
Drugs and Companies using COPPER CU-64 DOTATATE ingredient
NCE-1 date: 03 September, 2024
Market Authorisation Date: 03 September, 2020
Treatment: Use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients
Dosage: SOLUTION;INTRAVENOUS
DETECTNET family patents
46. Dexilant patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9233103 | TAKEDA PHARMS USA | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 30, 2012 |
| New Patient Population(NPP) | Jul 08, 2019 |
| Pediatric Exclusivity(PED) | Jul 30, 2012 |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: Use of dexlansoprazole in patients taking clopidogrel without meaningful cyp2c19 interactions
Dosage: CAPSULE, DELAYED RELEASE;ORAL
DEXILANT family patents
47. Dexycu Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10799642 | EYEPOINT PHARMS | Dose guides for injection syringe |
May, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 09, 2021 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 09 February, 2018
Treatment: NA
Dosage: SUSPENSION;INTRAOCULAR
DEXYCU KIT family patents
48. Dilaudid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9731082 | FRESENIUS KABI USA | Drug container |
Apr, 2032
(7 years from now) | |
Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 January, 2020
Treatment: NA
Dosage: INJECTABLE;INJECTION
DILAUDID family patents
49. Dilaudid-hp patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9731082 | FRESENIUS KABI USA | Drug container |
Apr, 2032
(7 years from now) | |
Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 January, 2020
Treatment: NA
Dosage: INJECTABLE;INJECTION
DILAUDID-HP family patents
50. Duzallo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8546436 | IRONWOOD PHARMS INC | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
Feb, 2032
(7 years from now) | |
Drugs and Companies using ALLOPURINOL; LESINURAD ingredient
Market Authorisation Date: 18 August, 2017
Treatment: NA
Dosage: TABLET;ORAL
DUZALLO family patents
51. Epaned Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8568747 | SILVERGATE PHARMS | Enalapril compositions |
Nov, 2032
(8 years from now) | |
| US9968553 | SILVERGATE PHARMS | Enalapril compositions |
Nov, 2032
(8 years from now) | |
| US9855214 | SILVERGATE PHARMS | Enalapril compositions |
Nov, 2032
(8 years from now) | |
| US8778366 | SILVERGATE PHARMS | Enalapril compositions |
Nov, 2032
(8 years from now) | |
Drugs and Companies using ENALAPRIL MALEATE ingredient
Market Authorisation Date: 13 August, 2013
Treatment: Treatment of heart failure; Method of treating left ventricular dysfunction
Dosage: FOR SOLUTION;ORAL
EPANED KIT family patents
52. Epclusa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8940718 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
| US8921341 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
| US8575135 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-376) | Jun 10, 2028 |
| M(M-277) | Apr 27, 2025 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
Market Authorisation Date: 10 June, 2021
Treatment: For the treatment of hepatitis c
Dosage: PELLETS;ORAL; TABLET;ORAL
EPCLUSA family patents
53. Epsolay patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9687465 | GALDERMA LABS LP | Compositions for the treatment of rosacea |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 22, 2025 |
Drugs and Companies using BENZOYL PEROXIDE ingredient
Market Authorisation Date: 22 April, 2022
Treatment: Topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older
Dosage: CREAM;TOPICAL
EPSOLAY family patents
54. Evotaz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039718 | BRISTOL | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
Drugs and Companies using ATAZANAVIR SULFATE; COBICISTAT ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 29 January, 2015
Treatment: NA
Dosage: TABLET;ORAL
EVOTAZ family patents
55. Evzio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8627816 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2032
(7 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: NA
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
EVZIO family patents
56. Evzio (autoinjector) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8627816 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2032
(7 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: NA
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
EVZIO (AUTOINJECTOR) family patents
57. Fetzima patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8865937 | ABBVIE | Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide |
May, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE*(NCE*) | Jul 25, 2018 |
| M(M-249) | Oct 07, 2022 |
Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient
Market Authorisation Date: 25 July, 2013
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
FETZIMA family patents
58. Fiasp Flextouch patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 19, 2022 |
| New Product(NP) | Sep 29, 2020 |
| M(M-247) | Oct 21, 2022 |
Drugs and Companies using INSULIN ASPART ingredient
Market Authorisation Date: 29 September, 2017
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
FIASP FLEXTOUCH family patents
59. Firdapse patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11060128 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(8 years from now) | |
| US11274331 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(8 years from now) | |
| US11274332 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(8 years from now) | |
| US11268128 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-223) | Nov 28, 2025 |
| New Patient Population(NPP) | Sep 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 28, 2023 |
Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient
NCE-1 date: 28 November, 2022
Market Authorisation Date: 28 November, 2018
Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine
Dosage: TABLET;ORAL
FIRDAPSE family patents
60. Firmagon patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11826397 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(8 years from now) | |
| US11766468 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(8 years from now) | |
| US10695398 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(8 years from now) | |
| US9415085 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 24, 2013 |
Drugs and Companies using DEGARELIX ACETATE ingredient
NCE-1 date: 24 December, 2012
Market Authorisation Date: 24 December, 2008
Treatment: Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect; Method of treating prostate cancer
Dosage: POWDER;SUBCUTANEOUS
FIRMAGON family patents
61. Genvoya patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039718 | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 25, 2020 |
| New Dosing Schedule(D-173) | Dec 10, 2021 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 05 November, 2015
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
GENVOYA family patents
62. Gilenya patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9592208 | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Mar, 2032
(7 years from now) | |
|
US9592208 (Pediatric) | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Sep, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | May 11, 2021 |
| New Patient Population(NPP) | May 11, 2021 |
| Pediatric Exclusivity(PED) | Nov 11, 2021 |
| M(M-106) | Jul 20, 2014 |
| New Chemical Entity Exclusivity(NCE) | Sep 21, 2015 |
Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient
NCE-1 date: 11 November, 2020
Market Authorisation Date: 11 May, 2018
Treatment: Treatment of multiple sclerosis in the pediatric patient population with 0.25 mg fingolimod
Dosage: CAPSULE;ORAL
GILENYA family patents
63. Gonitro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9101592 | POHL BOSKAMP | Stabilized granules containing glyceryl trinitrate |
Mar, 2032
(7 years from now) | |
Drugs and Companies using NITROGLYCERIN ingredient
Market Authorisation Date: 08 June, 2016
Treatment: NA
Dosage: POWDER;SUBLINGUAL
GONITRO family patents
64. Harvoni patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9393256 | GILEAD SCIENCES INC | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US10456414 | GILEAD SCIENCES INC | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-263) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-262) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-264) | Aug 28, 2026 |
| New Dosing Schedule(D-177) | Nov 15, 2022 |
Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient
Market Authorisation Date: 28 August, 2019
Treatment: For the treatment of hepatitis c
Dosage: PELLETS;ORAL; TABLET;ORAL
HARVONI family patents
65. Hepzato patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10369264 | DELCATH SYSTEMS INC | Apparatus for removing chemotherapy compounds from blood |
Nov, 2032
(8 years from now) | |
| US10569004 | DELCATH SYSTEMS INC | Apparatus for removing chemotherapy compounds from blood |
Nov, 2032
(8 years from now) | |
| US11633528 | DELCATH SYSTEMS INC | Apparatus for removing chemotherapy compounds from blood |
Nov, 2032
(8 years from now) | |
| US10098997 | DELCATH SYSTEMS INC | Apparatus for removing chemotherapy compounds from blood |
Nov, 2032
(8 years from now) | |
| US11241522 | DELCATH SYSTEMS INC | Apparatus for removing chemotherapy compounds from blood |
Nov, 2032
(8 years from now) | |
| US11083831 | DELCATH SYSTEMS INC | Filter and frame apparatus and method of use |
Dec, 2032
(8 years from now) | |
| US11833286 | DELCATH SYSTEMS INC | Filter and frame apparatus and method of use |
Dec, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 14, 2026 |
| Orphan Drug Exclusivity(ODE-438) | Aug 14, 2030 |
Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient
Market Authorisation Date: 14 August, 2023
Treatment: A method of treating a patient with uveal melanoma with unresectable hepatic metastases; A percutaneous hepatic perfusion procedure for treating a patient with uveal melanoma with unresectable hepatic...
Dosage: POWDER;INTRA-ARTERIAL
HEPZATO family patents
66. Ilevro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8921337 | HARROW EYE | Carboxyvinyl polymer-containing nanoparticle suspensions |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 16, 2015 |
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 16 October, 2012
Treatment: NA
Dosage: SUSPENSION/DROPS;OPHTHALMIC
ILEVRO family patents
67. Imvexxy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11241445 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US9289382 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US10835487 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US11304959 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US10537581 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US11497709 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US11351182 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US10806697 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US11246875 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 29, 2021 |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 29 May, 2018
Treatment: Treatment of dyspareunia; Treatment of a symptom of vulvar and vaginal atrophy
Dosage: INSERT;VAGINAL
IMVEXXY family patents
68. Inbrija patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9393210 | ACORDA | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(8 years from now) | |
| US8545878 | ACORDA | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(8 years from now) | |
| US8945612 | ACORDA | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(8 years from now) | |
| US8685442 | ACORDA | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 21, 2021 |
Drugs and Companies using LEVODOPA ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER;INHALATION
INBRIJA family patents
69. Inrebic patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10391094 | IMPACT | Compositions and methods for treating myelofibrosis |
Jun, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-259) | Aug 16, 2026 |
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis
Dosage: CAPSULE;ORAL
INREBIC family patents
70. Ionsys patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8781571 | THE MEDICINES CO | Switch validation circuit and method |
Mar, 2032
(7 years from now) | |
| US8428708 | THE MEDICINES CO | Self-test for analgesic product |
May, 2032
(8 years from now) | |
| US8428709 | THE MEDICINES CO | Current control for electrotransport drug delivery |
Jun, 2032
(8 years from now) | |
Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient
Market Authorisation Date: 22 May, 2006
Treatment: Method for iontophoretic transdermal delivery of fentanyl hydrochloride
Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL
IONSYS family patents
71. Isentress Hd patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10772888 | MSD SUB MERCK | Solid pharmaceutical compositions containing an integrase inhibitor |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | May 26, 2020 |
| New Dosing Schedule(D-167) | May 26, 2020 |
| New Patient Population(NPP) | Dec 21, 2014 |
| Pediatric Exclusivity(PED) | May 22, 2021 |
| M(M-114) | Mar 28, 2015 |
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2012 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
NCE-1 date: 22 May, 2020
Market Authorisation Date: 12 October, 2007
Treatment: Treatment of hiv-1 infection
Dosage: TABLET;ORAL
ISENTRESS HD family patents
72. Joenja patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8653092 | PHARMING | Tetrahydro-pyrido-pyrimidine derivatives |
Feb, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-430) | Mar 24, 2030 |
| New Chemical Entity Exclusivity(NCE) | Mar 24, 2028 |
Drugs and Companies using LENIOLISIB PHOSPHATE ingredient
NCE-1 date: 25 March, 2027
Market Authorisation Date: 24 March, 2023
Treatment: NA
Dosage: TABLET;ORAL
JOENJA family patents
73. Jornay Pm patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10292937 | IRONSHORE PHARMS | Methods of treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | |
| US8916588 | IRONSHORE PHARMS | Methods for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | |
| US9034902 | IRONSHORE PHARMS | Methods for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | |
| US9028868 | IRONSHORE PHARMS | Methods and compositions for treatment of attention deficit disorder |
Mar, 2032
(7 years from now) | |
| US9023389 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | |
| US9498447 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | |
| US9283214 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | |
| US9603809 | IRONSHORE PHARMS | Methods of treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | |
| US8927010 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | |
| US11241391 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | |
| US11241392 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | |
| US10905652 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | |
| US10182995 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | |
| US10881618 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | |
| US10617651 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 08, 2021 |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 08 August, 2018
Treatment: Method of treating attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
JORNAY PM family patents
74. Korlym patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10842801 | CORCEPT THERAP | Optimizing mifepristone absorption |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-22) | Feb 17, 2019 |
| New Product(NP) | Feb 17, 2015 |
| Orphan Drug Exclusivity(ODE) | Feb 17, 2019 |
Drugs and Companies using MIFEPRISTONE ingredient
Market Authorisation Date: 17 February, 2012
Treatment: Treating cushing's syndrome
Dosage: TABLET;ORAL
KORLYM family patents
75. Kuvan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216178 | BIOMARIN PHARM | Dry blend formulation of tetrahydrobiopterin |
Nov, 2032
(8 years from now) | |
Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient
Market Authorisation Date: 19 December, 2013
Treatment: NA
Dosage: POWDER;ORAL
KUVAN family patents
76. Lazanda patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9731869 | BTCP PHARMA | Container |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jun 30, 2014 |
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 30 June, 2011
Treatment: NA
Dosage: SPRAY, METERED;NASAL
LAZANDA family patents
77. Levemir Flexpen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-117) | May 18, 2015 |
| M(M-115) | Apr 06, 2015 |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
LEVEMIR FLEXPEN family patents
78. Levemir Flextouch patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9132239 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-117) | May 18, 2015 |
| M(M-115) | Apr 06, 2015 |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
LEVEMIR FLEXTOUCH family patents
79. Levothyroxine Sodium patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9168238 | FRESENIUS KABI USA | Levothyroxine formulations |
Aug, 2032
(8 years from now) | |
| US9168239 | FRESENIUS KABI USA | Levothyroxine formulations |
Aug, 2032
(8 years from now) | |
| US9006289 | FRESENIUS KABI USA | Levothyroxine formulations |
Oct, 2032
(8 years from now) | |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 24 June, 2011
Treatment: NA
Dosage: POWDER;INTRAVENOUS
LEVOTHYROXINE SODIUM family patents
80. Livmarli patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11376251 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2026 |
| Orphan Drug Exclusivity(ODE-429) | Mar 13, 2030 |
| New Indication(I-938) | Mar 13, 2027 |
| Orphan Drug Exclusivity(ODE-379) | Sep 29, 2028 |
| New Patient Population(NPP) | Mar 13, 2026 |
Drugs and Companies using MARALIXIBAT CHLORIDE ingredient
NCE-1 date: 29 September, 2025
Market Authorisation Date: 29 September, 2021
Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)
Dosage: SOLUTION;ORAL
LIVMARLI family patents
81. Livtencity patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11684632 | TAKEDA PHARMS USA | Maribavir isomers, compositions, methods of making and methods of using |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2026 |
| Orphan Drug Exclusivity(ODE-388) | Nov 23, 2028 |
Drugs and Companies using MARIBAVIR ingredient
NCE-1 date: 23 November, 2025
Market Authorisation Date: 23 November, 2021
Treatment: Treatment of patients with post-transplant cytomegalovirus (cmv) infection/disease refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet, where the patient is a stem cell, ...
Dosage: TABLET;ORAL
LIVTENCITY family patents
82. Lokelma patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11406662 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(7 years from now) | |
| US10413569 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(7 years from now) | |
| US8802152 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Apr, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8808750 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(7 years from now) | |
| US10335432 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(7 years from now) | |
| US9861658 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(7 years from now) | |
| US9844567 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(7 years from now) | |
| US10398730 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 18, 2023 |
| M(M-261) | Apr 24, 2023 |
Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient
NCE-1 date: 18 May, 2022
Market Authorisation Date: 18 May, 2018
Treatment: Treatment of hyperkalemia in adults
Dosage: FOR SUSPENSION;ORAL
LOKELMA family patents
83. Lonhala Magnair Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9168556 | SUMITOMO PHARMA AM | Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer |
Sep, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 05, 2020 |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION;INHALATION
LONHALA MAGNAIR KIT family patents
84. Lybalvi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778960 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Feb, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain
Dosage: TABLET;ORAL
LYBALVI family patents
85. Mavyret patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8648037 | ABBVIE | Macrocyclic proline derived HCV serine protease inhibitors |
Jan, 2032
(7 years from now) | |
| US8937150 | ABBVIE | Anti-viral compounds |
May, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8648037 (Pediatric) | ABBVIE | Macrocyclic proline derived HCV serine protease inhibitors |
Jul, 2032
(8 years from now) | |
|
US8937150 (Pediatric) | ABBVIE | Anti-viral compounds |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-372) | Jun 10, 2028 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
| New Chemical Entity Exclusivity(NCE) | Aug 03, 2022 |
| New Dosing Schedule(D-175) | Sep 26, 2022 |
| M(M-259) | Apr 10, 2023 |
Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient
NCE-1 date: 11 December, 2027
Market Authorisation Date: 10 June, 2021
Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg
Dosage: PELLETS;ORAL; TABLET;ORAL
MAVYRET family patents
86. Mekinist patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9271941 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(7 years from now) | |
| US9399021 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(7 years from now) | |
| US9155706 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(7 years from now) | |
| US8580304 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(7 years from now) | |
|
US9155706 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
|
US9271941 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
|
US9399021 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
|
US8580304 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| Orphan Drug Exclusivity(ODE-148) | Jun 22, 2024 |
| New Indication(I-908) | Mar 16, 2026 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
| New Indication(I-895) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Dec 22, 2025 |
| New Indication(I-745) | Jun 22, 2020 |
| Orphan Drug Exclusivity(ODE-48) | May 29, 2020 |
| M(M-170) | Nov 20, 2018 |
| Orphan Drug Exclusivity(ODE-57) | Jan 08, 2021 |
| New Indication(I-678) | Jan 08, 2017 |
| M(M-246) | Oct 06, 2022 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
NCE-1 date: 22 December, 2024
Market Authorisation Date: 29 May, 2013
Treatment: NA
Dosage: TABLET;ORAL
MEKINIST family patents
87. Movantik patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9012469 | VALINOR | Crystalline naloxol-peg conjugate |
Apr, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 16, 2019 |
Drugs and Companies using NALOXEGOL OXALATE ingredient
NCE-1 date: 16 September, 2018
Market Authorisation Date: 16 September, 2014
Treatment: NA
Dosage: TABLET;ORAL
MOVANTIK family patents
88. Neoprofen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8415337 | RECORDATI RARE | Ibuprofen compositions and methods of making same |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Apr 13, 2013 |
Drugs and Companies using IBUPROFEN LYSINE ingredient
Market Authorisation Date: 13 April, 2006
Treatment: NA
Dosage: INJECTABLE;INTRAVENOUS
NEOPROFEN family patents
89. Netspot patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9375498 | AAA USA INC | Process for the preparation of complexes of 68Ga |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-120) | Jun 01, 2023 |
| Orphan Drug Exclusivity(ODE) | Jun 01, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jun 01, 2021 |
Drugs and Companies using GALLIUM DOTATATE GA-68 ingredient
NCE-1 date: 01 June, 2020
Market Authorisation Date: 01 June, 2016
Treatment: NA
Dosage: POWDER;INTRAVENOUS
NETSPOT family patents
90. Neupro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9925150 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 09, 2012 |
| New Indication(I-647) | Apr 02, 2015 |
| New Indication(I-646) | Apr 02, 2015 |
Drugs and Companies using ROTIGOTINE ingredient
NCE-1 date: 10 May, 2011
Market Authorisation Date: 02 April, 2012
Treatment: NA
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
NEUPRO family patents
91. Norditropin Flexpro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9132239 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN ingredient
Market Authorisation Date: 23 January, 2015
Treatment: NA
Dosage: INJECTABLE;INJECTION
NORDITROPIN FLEXPRO family patents
92. Novolog Flexpen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(8 years from now) | |
Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
NOVOLOG FLEXPEN family patents
93. Novolog Flextouch patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9132239 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
NOVOLOG FLEXTOUCH family patents
94. Novolog Mix 70/30 Flexpen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(8 years from now) | |
Market Authorisation Date: 01 November, 2001
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
NOVOLOG MIX 70/30 FLEXPEN family patents
95. Nuvessa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8946276 | CHEMO RESEARCH SL | High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis |
Jun, 2032
(8 years from now) | |
| US10238634 | CHEMO RESEARCH SL | Aqueous-based metronidazole gel formulations |
Jun, 2032
(8 years from now) | |
| US9198858 | CHEMO RESEARCH SL | Methods of treating bacterial vaginosis with aqueous-based metronidazole gel formulations |
Jun, 2032
(8 years from now) | |
| US10596155 | CHEMO RESEARCH SL | Aqueous-based metronidazole gel formulations |
Jun, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 24, 2017 |
Drugs and Companies using METRONIDAZOLE ingredient
Market Authorisation Date: 24 March, 2014
Treatment: Treatment of bacterial vaginosis with metronidazole gel
Dosage: GEL;VAGINAL
NUVESSA family patents
96. Odefsey patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| M(M-207) | Aug 21, 2020 |
| M(M-206) | Aug 21, 2020 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 01 March, 2016
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
ODEFSEY family patents
97. Ofirmev patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9399012 (Pediatric) | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-196) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
| New Product(NP) | Nov 02, 2013 |
Drugs and Companies using ACETAMINOPHEN ingredient
Market Authorisation Date: 02 November, 2010
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
OFIRMEV family patents
98. Olinvyk patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11077098 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(7 years from now) | |
| US8835488 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(7 years from now) | |
| US9309234 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9642842 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 30, 2025 |
Drugs and Companies using OLICERIDINE ingredient
NCE-1 date: 30 October, 2024
Market Authorisation Date: 30 October, 2020
Treatment: Management of acute pain by intravenous injection
Dosage: SOLUTION;INTRAVENOUS
OLINVYK family patents
99. Olumiant patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11045474 | ELI LILLY AND CO | Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections |
Nov, 2032
(8 years from now) | |
| US9089574 | ELI LILLY AND CO | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-890) | Jun 13, 2025 |
| New Indication(I-891) | May 10, 2025 |
| New Chemical Entity Exclusivity(NCE) | May 31, 2023 |
Drugs and Companies using BARICITINIB ingredient
NCE-1 date: 31 May, 2022
Market Authorisation Date: 08 October, 2019
Treatment: Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo)
Dosage: TABLET;ORAL
OLUMIANT family patents
100. Ongentys patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9630955 | NEUROCRINE | Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor |
Dec, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2025 |
Drugs and Companies using OPICAPONE ingredient
NCE-1 date: 24 April, 2024
Market Authorisation Date: 24 April, 2020
Treatment: Method of treating parkinson's disease
Dosage: CAPSULE;ORAL
ONGENTYS family patents
101. Oxbryta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10806733 | GLOBAL BLOOD THERAPS | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
Dec, 2032
(8 years from now) | |
| US10034879 | GLOBAL BLOOD THERAPS | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
Dec, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10017491 | GLOBAL BLOOD THERAPS | Compounds and uses thereof for the modulation of hemoglobin |
Dec, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-281) | Nov 25, 2026 |
| New Chemical Entity Exclusivity(NCE) | Nov 25, 2024 |
| Orphan Drug Exclusivity(ODE-394) | Dec 17, 2028 |
Drugs and Companies using VOXELOTOR ingredient
NCE-1 date: 26 November, 2023
Market Authorisation Date: 14 October, 2022
Treatment: NA
Dosage: TABLET;ORAL; TABLET, FOR SUSPENSION;ORAL
OXBRYTA family patents
102. Ozempic patents expiration
What is Ozempic?
Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.
What is the Ozempic controversy?
The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-185) | Mar 28, 2025 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Indication(I-822) | Jan 16, 2023 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
OZEMPIC family patents
103. Pataday Once Daily Relief patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9533053 | ALCON LABS INC | High concentration olopatadine ophthalmic composition |
May, 2032
(8 years from now) | |
| US8791154 | ALCON LABS INC | High concentration olopatadine ophthalmic composition |
May, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 30, 2018 |
| Pediatric Exclusivity(PED) | Jul 30, 2018 |
Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 2015
Treatment: Treatment of ocular itching associated with allergic conjunctivitis
Dosage: SOLUTION/DROPS;OPHTHALMIC
PATADAY ONCE DAILY RELIEF family patents
104. Pepaxto patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10869928 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(8 years from now) | |
| US10285946 | ONCOPEPTIDES AB | Lyophilized preparations of melphalan flufenamide |
Apr, 2032
(8 years from now) | |
| US10543274 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(8 years from now) | |
| US10322182 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(8 years from now) | |
| US11344622 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-348) | Feb 26, 2028 |
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2026 |
Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient
NCE-1 date: 26 February, 2025
Market Authorisation Date: 26 February, 2021
Treatment: In combination with dexamethasone to treat relapsed or refractory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received ...
Dosage: POWDER;INTRAVENOUS
PEPAXTO family patents
105. Plenvu patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11529368 | SALIX | Colonoscopy—preparation |
Mar, 2032
(7 years from now) | |
| US10780112 | SALIX | Colonoscopy-preparation |
Mar, 2032
(7 years from now) | |
| US10792306 | SALIX | Colonoscopy—preparation |
Mar, 2032
(7 years from now) | |
| US10646512 | SALIX | Colonoscopy - preparation |
Mar, 2032
(7 years from now) | |
| US9592252 | SALIX | Colonoscopy—preparation |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 04, 2021 |
Market Authorisation Date: 04 May, 2018
Treatment: For cleansing of the colon in preparation for colonoscopy in adults
Dosage: FOR SOLUTION;ORAL
PLENVU family patents
106. Ponvory patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9062014 | JANSSEN PHARMS | Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one |
May, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 18, 2026 |
Drugs and Companies using PONESIMOD ingredient
NCE-1 date: 18 March, 2025
Market Authorisation Date: 18 March, 2021
Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
Dosage: TABLET;ORAL
PONVORY family patents
107. Precedex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8338470 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(7 years from now) | |
| US8242158 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(7 years from now) | |
| US8455527 | HOSPIRA | Methods of treatment using a dexmedetomidine premix formulation |
Jan, 2032
(7 years from now) | |
| US9616049 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(7 years from now) | |
| US9320712 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(7 years from now) | |
| US10016396 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(7 years from now) | |
| US8648106 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(7 years from now) | |
|
US9320712 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(8 years from now) | |
|
US8242158 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(8 years from now) | |
|
US8455527 (Pediatric) | HOSPIRA | Methods of treatment using a dexmedetomidine premix formulation |
Jul, 2032
(8 years from now) | |
|
US9616049 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(8 years from now) | |
|
US8338470 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(8 years from now) | |
|
US8648106 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2025 |
| New Indication(I-577) | Oct 17, 2011 |
| M(M-61) | Jun 17, 2016 |
| Pediatric Exclusivity(PED) | Dec 17, 2016 |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 31 January, 2020
Treatment: Use for sedation
Dosage: INJECTABLE;INJECTION
PRECEDEX family patents
108. Prezcobix patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039718 | JANSSEN PRODS | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
Drugs and Companies using COBICISTAT; DARUNAVIR ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 29 January, 2015
Treatment: NA
Dosage: TABLET;ORAL
PREZCOBIX family patents
109. Proair Digihaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
| US8978966 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 12, 2018 |
| New Patient Population(NPP) | Apr 28, 2019 |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER, METERED;INHALATION
PROAIR DIGIHALER family patents
110. Proair Hfa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 16, 2011 |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 29 October, 2004
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
PROAIR HFA family patents
111. Proair Respiclick patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
| US8978966 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 12, 2018 |
| New Patient Population(NPP) | Apr 28, 2019 |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER, METERED;INHALATION
PROAIR RESPICLICK family patents
112. Prolensa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10085958 | BAUSCH AND LOMB | Bromfenac bioavailability |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 05, 2016 |
Drugs and Companies using BROMFENAC SODIUM ingredient
Market Authorisation Date: 05 April, 2013
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
PROLENSA family patents
113. Pyrukynd patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10632114 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(8 years from now) | |
| US9682080 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(8 years from now) | |
| US9980961 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(8 years from now) | |
| US9193701 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
Oct, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-392) | Feb 17, 2029 |
| New Chemical Entity Exclusivity(NCE) | Feb 17, 2027 |
Drugs and Companies using MITAPIVAT SULFATE ingredient
NCE-1 date: 17 February, 2026
Market Authorisation Date: 17 February, 2022
Treatment: Method for increasing the lifetime of red blood cells (rbcs) for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method of using a pyruvate kinase activator for the t...
Dosage: TABLET;ORAL
PYRUKYND family patents
114. Qinlock patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8940756 | DECIPHERA PHARMS | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jun, 2032
(8 years from now) | |
| USRE48731 | DECIPHERA PHARMS | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jun, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2025 |
| Orphan Drug Exclusivity(ODE-298) | May 15, 2027 |
Drugs and Companies using RIPRETINIB ingredient
NCE-1 date: 15 May, 2024
Market Authorisation Date: 15 May, 2020
Treatment: Treatment of gastrointestinal stromal tumors; Treatment of gastrointestinal stromal tumor
Dosage: TABLET;ORAL
QINLOCK family patents
115. Qulipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8754096 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-909) | Apr 17, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2026 |
Drugs and Companies using ATOGEPANT ingredient
NCE-1 date: 28 September, 2025
Market Authorisation Date: 28 September, 2021
Treatment: Preventive treatment of migraine in adults
Dosage: TABLET;ORAL
QULIPTA family patents
116. Qvar 40 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 15 September, 2000
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
QVAR 40 family patents
117. Qvar 80 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 15 September, 2000
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
QVAR 80 family patents
118. Qvar Redihaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | NORTON WATERFORD | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 03 August, 2017
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
QVAR REDIHALER family patents
119. Ravicti patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9095559 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Mar, 2032
(7 years from now) | |
| US9254278 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Mar, 2032
(7 years from now) | |
| US9326966 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Mar, 2032
(7 years from now) | |
| US8404215 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-157) | Apr 28, 2024 |
| New Patient Population(NPP) | Dec 21, 2021 |
| Orphan Drug Exclusivity(ODE-42) | Feb 01, 2020 |
| NE(NE) | Feb 01, 2016 |
| Orphan Drug Exclusivity(ODE) | Feb 01, 2020 |
Drugs and Companies using GLYCEROL PHENYLBUTYRATE ingredient
Market Authorisation Date: 01 February, 2013
Treatment: Dosage adjustment of a nitrogen scavenging drug in the treatment of a urea cycle disorder; Treatment of a urea cycle disorder
Dosage: LIQUID;ORAL
RAVICTI family patents
120. Restasis Multidose patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8561859 | ABBVIE | Dispensing device |
Apr, 2032
(7 years from now) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: NA
Dosage: EMULSION;OPHTHALMIC
RESTASIS MULTIDOSE family patents
121. Rexulti patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10307419 | OTSUKA | Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof |
Oct, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 27, 2024 |
| New Indication(I-913) | May 10, 2026 |
| M(M-186) | Sep 23, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 10, 2020 |
Drugs and Companies using BREXPIPRAZOLE ingredient
NCE-1 date: 11 July, 2019
Market Authorisation Date: 10 July, 2015
Treatment: NA
Dosage: TABLET;ORAL
REXULTI family patents
122. Rezzayo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11654196 | CIDARA THERAPS | Dosing regimens for echinocandin class compounds |
Mar, 2032
(7 years from now) | |
| US8722619 | CIDARA THERAPS | Antifungal agents and uses thereof |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Generating Antibiotic Incentives Now(GAIN) | Mar 22, 2033 |
| Orphan Drug Exclusivity(ODE-426) | Mar 22, 2030 |
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2028 |
Drugs and Companies using REZAFUNGIN ACETATE ingredient
NCE-1 date: 22 March, 2032
Market Authorisation Date: 22 March, 2023
Treatment: Treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration
Dosage: POWDER;INTRAVENOUS
REZZAYO family patents
123. Rivive patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11020343 | HARM REDUCTION THERP | Intranasal pharmaceutical dosage forms comprising naloxone |
May, 2032
(8 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 July, 2023
Treatment: Use of intranasal naloxone for the treatment of opioid overdose
Dosage: SPRAY, METERED;NASAL
RIVIVE family patents
124. Rykindo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9446135 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(7 years from now) | |
| US9532991 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(7 years from now) | |
| US11110094 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(7 years from now) | |
| US10406161 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(7 years from now) | |
| US10098882 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(7 years from now) | |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 13 January, 2023
Treatment: Treatment of schizophrenia in adults
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
RYKINDO family patents
125. Ryzodeg 70/30 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN ASPART; INSULIN DEGLUDEC ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 25 September, 2015
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
RYZODEG 70/30 family patents
126. Saxenda patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
|
US9132239 (Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 04, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
| New Product(NP) | Jan 25, 2017 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
NCE-1 date: 25 January, 2014
Market Authorisation Date: 23 December, 2014
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
SAXENDA family patents
127. Sinuva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8763222 | INTERSECT ENT INC | Methods and devices for crimping self-expanding devices |
Feb, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 08, 2020 |
Drugs and Companies using MOMETASONE FUROATE ingredient
Market Authorisation Date: 08 December, 2017
Treatment: NA
Dosage: IMPLANT;IMPLANTATION
SINUVA family patents
128. Soliqua 100/33 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9821032 | SANOFI-AVENTIS US | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
May, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 21 November, 2016
Treatment: Improvement of glycemic control in type 2 diabetes mellitus patients
Dosage: SOLUTION;SUBCUTANEOUS
SOLIQUA 100/33 family patents
129. Stivarga patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9957232 | BAYER HLTHCARE | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate |
Jul, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-139) | Apr 27, 2024 |
| New Indication(I-744) | Apr 27, 2020 |
| Orphan Drug Exclusivity(ODE-44) | Feb 25, 2020 |
| Orphan Drug Exclusivity(ODE) | Feb 25, 2020 |
| New Chemical Entity Exclusivity(NCE) | Sep 27, 2017 |
| New Indication(I-667) | Feb 25, 2016 |
Drugs and Companies using REGORAFENIB ingredient
NCE-1 date: 27 September, 2016
Market Authorisation Date: 27 September, 2012
Treatment: NA
Dosage: TABLET;ORAL
STIVARGA family patents
130. Stribild patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039718 | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-704) | Dec 17, 2017 |
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Patient Population(NPP) | Jan 27, 2020 |
| New Product(NP) | Aug 27, 2015 |
NCE-1 date: 27 August, 2016
Market Authorisation Date: 27 August, 2012
Treatment: NA
Dosage: TABLET;ORAL
STRIBILD family patents
131. Sublocade patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8921387 | INDIVIOR | Injectable flowable composition comprising buprenorphine |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 30, 2020 |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 30 November, 2017
Treatment: Treating opioid dependency by administering buprenorphine once per month
Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS
SUBLOCADE family patents
132. Symtuza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9296769 | JANSSEN PRODS | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| US8754065 | JANSSEN PRODS | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039718 | JANSSEN PRODS | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Combination(NC) | Jul 17, 2021 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 17 July, 2018
Treatment: Treatment of hiv-1 infection in adults and pediatric patients weighing at least 40 kg who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regi...
Dosage: TABLET;ORAL
SYMTUZA family patents
133. Synjardy Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10596120 | BOEHRINGER INGELHEIM | Pharmaceutical compositions |
Mar, 2032
(7 years from now) | |
|
US10596120 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical compositions |
Sep, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-296) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 09 December, 2016
Treatment: Treatment of a treatment-naïve patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprising metformin and an outer coating comprising empagli...
Dosage: TABLET, EXTENDED RELEASE;ORAL
SYNJARDY XR family patents
134. Tagrisso patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9732058 | ASTRAZENECA | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Jul, 2032
(8 years from now) | |
| US11524951 | ASTRAZENECA | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Jul, 2032
(8 years from now) | |
| US8946235 | ASTRAZENECA | 2-(2,4,5-substituted-anilino) pyrimidine compounds |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-176) | Apr 18, 2025 |
| Orphan Drug Exclusivity(ODE-337) | Dec 18, 2027 |
| Orphan Drug Exclusivity(ODE-102) | Nov 13, 2022 |
| New Indication(I-774) | Apr 18, 2021 |
| New Indication(I-853) | Dec 18, 2023 |
| Orphan Drug Exclusivity(ODE) | Nov 13, 2022 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2020 |
Drugs and Companies using OSIMERTINIB MESYLATE ingredient
NCE-1 date: 14 November, 2019
Market Authorisation Date: 13 November, 2015
Treatment: Adjuvant therapy after tumor resection in patients with non-small cell lung cancer(nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19deletions or exon 21 l858r mutations
Dosage: TABLET;ORAL
TAGRISSO family patents
135. Tasigna patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9061029 | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Apr, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9061029 (Pediatric) | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Oct, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Mar 23, 2029 |
| Orphan Drug Exclusivity(ODE-171) | Mar 22, 2025 |
| Orphan Drug Exclusivity(ODE-172) | Mar 22, 2025 |
| Orphan Drug Exclusivity(ODE-380) | Sep 23, 2028 |
| New Dosing Schedule(D-170) | Dec 22, 2020 |
| New Patient Population(NPP) | Mar 22, 2021 |
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2012 |
| New Indication(I-627) | Jun 17, 2014 |
| Orphan Drug Exclusivity(ODE) | Oct 29, 2014 |
Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 23 March, 2028
Market Authorisation Date: 22 March, 2018
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml) by administering nilotinib dispersed in a fruit preparation
Dosage: CAPSULE;ORAL
TASIGNA family patents
136. Tauvid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8932557 | AVID RADIOPHARMS INC | Imaging agents for detecting neurological dysfunction |
May, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2025 |
Drugs and Companies using FLORTAUCIPIR F-18 ingredient
NCE-1 date: 28 May, 2024
Market Authorisation Date: 28 May, 2020
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
TAUVID family patents
137. Tavalisse patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8771648 | RIGEL PHARMS INC | (Trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(8 years from now) | |
| US8951504 | RIGEL PHARMS INC | (trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-174) | Apr 17, 2025 |
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2023 |
Drugs and Companies using FOSTAMATINIB DISODIUM ingredient
NCE-1 date: 17 April, 2022
Market Authorisation Date: 17 April, 2018
Treatment: Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment
Dosage: TABLET;ORAL
TAVALISSE family patents
138. Tazverik patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11052093 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Apr, 2032
(7 years from now) | |
| US9090562 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9522152 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(7 years from now) | |
| US10155002 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(7 years from now) | |
| US9549931 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(7 years from now) | |
| US9855275 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Apr, 2032
(7 years from now) | |
| US10420775 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Apr, 2032
(7 years from now) | |
| US8765732 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 23, 2025 |
| Orphan Drug Exclusivity(ODE-314) | Jun 18, 2027 |
| Orphan Drug Exclusivity(ODE-299) | Jan 23, 2027 |
| New Indication(I-835) | Jun 18, 2023 |
| New Indication(I-836) | Jun 18, 2023 |
Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient
NCE-1 date: 24 January, 2024
Market Authorisation Date: 23 January, 2020
Treatment: Method of treating a lung metastasis of epithelioid sarcoma; Method of treating epithelioid sarcoma; Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste hom...
Dosage: TABLET;ORAL
TAZVERIK family patents
139. Technivie patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8691938 | ABBVIE | Anti-viral compounds |
Apr, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 24, 2018 |
| New Indication(I-743) | Jul 24, 2018 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 24 July, 2015
Treatment: NA
Dosage: TABLET;ORAL
TECHNIVIE family patents
140. Torisel patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791097 | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
May, 2032
(8 years from now) | |
|
US8791097 (Pediatric) | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | May 30, 2015 |
| M(M-92) | Jul 09, 2013 |
| Orphan Drug Exclusivity(ODE) | May 30, 2014 |
| M(M-91) | Apr 26, 2013 |
| Pediatric Exclusivity(PED) | Jan 09, 2014 |
Drugs and Companies using TEMSIROLIMUS ingredient
Market Authorisation Date: 30 May, 2007
Treatment: Method of treating metastatic papillary renal cell carcinoma with temsirolimus.
Dosage: SOLUTION;INTRAVENOUS
TORISEL family patents
141. Tresiba patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN DEGLUDEC ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 21 November, 2018
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
TRESIBA family patents
142. Trijardy Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11564886 | BOEHRINGER INGELHEIM | Pharmaceutical compositions |
Mar, 2032
(7 years from now) | |
| US10596120 | BOEHRINGER INGELHEIM | Pharmaceutical compositions |
Mar, 2032
(7 years from now) | |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 January, 2020
Treatment: Treatment of a type 2 diabetes patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating co...
Dosage: TABLET, EXTENDED RELEASE;ORAL
TRIJARDY XR family patents
143. Trintellix patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9278096 | TAKEDA PHARMS USA | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity |
Mar, 2032
(7 years from now) | |
|
US9278096 (Pediatric) | TAKEDA PHARMS USA | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity |
Sep, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-187) | Jan 22, 2024 |
| M(M-232) | Aug 23, 2026 |
| Pediatric Exclusivity(PED) | Feb 23, 2027 |
| New Chemical Entity Exclusivity(NCE) | Sep 30, 2018 |
| M(M-227) | May 02, 2021 |
| M(M-234) | Oct 19, 2021 |
| M(M-267) | Nov 13, 2023 |
Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient
NCE-1 date: 23 February, 2026
Market Authorisation Date: 30 September, 2013
Treatment: Use in the treatment of major depressive disorder to improve treatment emergent sexual dysfunction (tesd) induced by prior serotonin reuptake inhibitor treatment
Dosage: TABLET;ORAL
TRINTELLIX family patents
144. Trudhesa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9550036 | IMPEL PHARMS | Nasal drug delivery device |
Sep, 2032
(8 years from now) | |
| US10507295 | IMPEL PHARMS | Nasal drug delivery device |
Dec, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 02, 2024 |
Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient
Market Authorisation Date: 02 September, 2021
Treatment: NA
Dosage: SPRAY, METERED;NASAL
TRUDHESA family patents
145. Trulance patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11319346 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Mar, 2032
(7 years from now) | |
| US9616097 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 19, 2022 |
| New Indication(I-764) | Jan 24, 2021 |
Drugs and Companies using PLECANATIDE ingredient
NCE-1 date: 19 January, 2021
Market Authorisation Date: 19 January, 2017
Treatment: NA
Dosage: TABLET;ORAL
TRULANCE family patents
146. Tukysa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9457093 | SEAGEN | Solid dispersions of a ERB2 (HER2) inhibitor |
Oct, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-309) | Apr 17, 2027 |
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
| New Indication(I-906) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-422) | Jan 19, 2030 |
Drugs and Companies using TUCATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer
Dosage: TABLET;ORAL
TUKYSA family patents
147. Tuxarin Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9107921 | MAINPOINTE | Oral dosage forms for oxygen containing active agents and oxyl-containing polymers |
Jan, 2032
(7 years from now) | |
| US9066942 | MAINPOINTE | Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer |
Jan, 2032
(7 years from now) | |
Drugs and Companies using CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE ingredient
Market Authorisation Date: 22 June, 2015
Treatment: Treatment of cough and symptoms associated with upper respiratory allergies or a common cold with codeine phosphate and chlorpheniramine maleate orally administered extended release tablets
Dosage: TABLET, EXTENDED RELEASE;ORAL
TUXARIN ER family patents
148. Tybost patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039718 | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-260) | Aug 22, 2026 |
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Product(NP) | Sep 24, 2017 |
| New Patient Population(NPP) | Aug 22, 2022 |
Drugs and Companies using COBICISTAT ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 24 September, 2014
Treatment: NA
Dosage: TABLET;ORAL
TYBOST family patents
149. Ubrelvy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8754096 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 24 December, 2023
Market Authorisation Date: 23 December, 2019
Treatment: Acute treatment of migraine with headache, with or without aura in adults
Dosage: TABLET;ORAL
UBRELVY family patents
150. Varithena patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9480652 | PROVENSIS | Aerosol valve |
May, 2032
(8 years from now) | |
Drugs and Companies using POLIDOCANOL ingredient
Market Authorisation Date: 21 December, 2017
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
VARITHENA family patents
151. Varubi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9101615 | TERSERA | Intravenous formulations of neurokinin-1 antagonists |
Jul, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 01, 2020 |
Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient
NCE-1 date: 02 September, 2019
Market Authorisation Date: 25 October, 2017
Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy
Dosage: EMULSION;INTRAVENOUS
VARUBI family patents
152. Vazalore patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10786444 | PLX PHARMA | PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
Sep, 2032
(8 years from now) | |
| US10646431 | PLX PHARMA | PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
Sep, 2032
(8 years from now) | |
| US9216150 | PLX PHARMA | pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
Sep, 2032
(8 years from now) | |
| US9226892 | PLX PHARMA | pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
Sep, 2032
(8 years from now) | |
Drugs and Companies using ASPIRIN ingredient
Market Authorisation Date: 26 February, 2021
Treatment: A method of targeting release of a non-steroidal anti-inflammatory drug (nsaid) to the small intestine of the subject when administered orally; Temporary reduction of fever
Dosage: CAPSULE;ORAL
VAZALORE family patents
153. Vemlidy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 17, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| M(M-255) | Feb 04, 2023 |
| M(M-266) | Aug 22, 2023 |
| New Product(NP) | Nov 11, 2019 |
Drugs and Companies using TENOFOVIR ALAFENAMIDE FUMARATE ingredient
NCE-1 date: 06 November, 2019
Market Authorisation Date: 10 November, 2016
Treatment: Treatment of chronic hepatitis b in adult patients; Treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and older
Dosage: TABLET;ORAL
VEMLIDY family patents
154. Venclexta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8722657 | ABBVIE | Salts and crystalline forms of an apoptosis-inducing agent |
Jan, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11369599 | ABBVIE | Melt-extruded solid dispersions containing an apoptosis-inducing agent |
May, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-185) | Jun 08, 2025 |
| Orphan Drug Exclusivity(ODE-211) | Nov 21, 2025 |
| Orphan Drug Exclusivity(ODE-239) | May 15, 2026 |
| New Chemical Entity Exclusivity(NCE) | Apr 11, 2021 |
| Orphan Drug Exclusivity(ODE) | Apr 11, 2023 |
| New Indication(I-789) | Nov 21, 2021 |
| New Indication(I-795) | May 15, 2022 |
| M(M-265) | Oct 16, 2023 |
| Orphan Drug Exclusivity(ODE-114) | Apr 11, 2023 |
| M(M-228) | Jun 08, 2021 |
| New Indication(I-782) | Jun 08, 2021 |
Drugs and Companies using VENETOCLAX ingredient
NCE-1 date: 11 April, 2020
Market Authorisation Date: 11 April, 2016
Treatment: NA
Dosage: TABLET;ORAL
VENCLEXTA family patents
155. Verquvo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9604948 | MERCK SHARP DOHME | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 19, 2026 |
Drugs and Companies using VERICIGUAT ingredient
NCE-1 date: 19 January, 2025
Market Authorisation Date: 19 January, 2021
Treatment: Reducing the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for hf or need for outpatient iv diuretics, in adults with symptomatic chronic hf and eject...
Dosage: TABLET;ORAL
VERQUVO family patents
156. Victoza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-176) | Apr 22, 2019 |
| New Patient Population(NPP) | Jun 17, 2022 |
| New Indication(I-750) | Aug 25, 2020 |
| Pediatric Exclusivity(PED) | Dec 17, 2022 |
| M(M-115) | Apr 06, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
NCE-1 date: 17 December, 2021
Market Authorisation Date: 25 January, 2010
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
VICTOZA family patents
157. Viekira Pak (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8691938 | ABBVIE | Anti-viral compounds |
Apr, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8466159 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8685984 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8680106 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8492386 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| New Dosing Schedule(D-163) | Apr 22, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin.; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavi...
Dosage: TABLET;ORAL
VIEKIRA PAK (COPACKAGED) family patents
158. Viekira Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8691938 | ABBVIE | Anti-viral compounds |
Apr, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10201584 | ABBVIE | Compositions and methods for treating HCV |
May, 2032
(8 years from now) | |
| US10201541 | ABBVIE | Compositions and methods for treating HCV |
May, 2032
(8 years from now) | |
| US8680106 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8466159 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8685984 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8492386 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 22 July, 2016
Treatment: Treatment of hcv infection using dasabuvir/ombitasvir/paritaprevir/ritonavir fixed dose combination; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin....
Dosage: TABLET, EXTENDED RELEASE;ORAL
VIEKIRA XR family patents
159. Vosevi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8940718 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
| US9868745 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
| US8921341 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
| US8575135 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 18, 2022 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient
NCE-1 date: 18 July, 2021
Market Authorisation Date: 18 July, 2017
Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor; Treatme...
Dosage: TABLET;ORAL
VOSEVI family patents
160. Vyxeos patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10835492 | CELATOR PHARMS | Method of lyophilizing liposomes |
Oct, 2032
(8 years from now) | |
| US10166184 | CELATOR PHARMS | Method of lyophilizing liposomes |
Oct, 2032
(8 years from now) | |
| US10028912 | CELATOR PHARMS | Method of lyophilizing liposomes |
Oct, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-350) | Mar 30, 2028 |
| New Patient Population(NPP) | Mar 30, 2024 |
| Orphan Drug Exclusivity(ODE-287) | Aug 03, 2024 |
| New Product(NP) | Aug 03, 2020 |
Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient
Market Authorisation Date: 03 August, 2017
Treatment: Method of administering a reconstituted liposomal composition containing cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (am...
Dosage: POWDER;INTRAVENOUS
VYXEOS family patents
161. Xartemis Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9468636 | MALLINCKRODT INC | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
May, 2032
(8 years from now) | |
| US9050335 | MALLINCKRODT INC | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
May, 2032
(8 years from now) | |
| US8992975 | MALLINCKRODT INC | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
May, 2032
(8 years from now) | |
| US8658631 | MALLINCKRODT INC | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
May, 2032
(8 years from now) | |
| US8741885 | MALLINCKRODT INC | Gastric retentive extended release pharmaceutical compositions |
May, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 11, 2017 |
Drugs and Companies using ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 11 March, 2014
Treatment: Management of acute pain in patients requiring opioid analgesia
Dosage: TABLET, EXTENDED RELEASE;ORAL
XARTEMIS XR family patents
162. Xcopri patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7598279 | SK LIFE | Neurotherapeutic azole compounds |
Oct, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2025 |
Drugs and Companies using CENOBAMATE ingredient
NCE-1 date: 10 March, 2024
Market Authorisation Date: 10 March, 2020
Treatment: NA
Dosage: TABLET;ORAL
XCOPRI family patents
163. Xepi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9180200 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 11, 2022 |
Drugs and Companies using OZENOXACIN ingredient
NCE-1 date: 11 December, 2021
Market Authorisation Date: 11 December, 2017
Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes
Dosage: CREAM;TOPICAL
XEPI family patents
164. Xpovio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9714226 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10544108 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(8 years from now) | |
| US11034660 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(8 years from now) | |
| US11787771 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(8 years from now) | |
| US9079865 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | Jul 03, 2026 |
| Orphan Drug Exclusivity(ODE-257) | Jul 03, 2026 |
| New Chemical Entity Exclusivity(NCE) | Jul 03, 2024 |
| Orphan Drug Exclusivity(ODE-310) | Jun 22, 2027 |
| Orphan Drug Exclusivity(ODE-346) | Dec 18, 2027 |
| New Indication(I-837) | Jun 22, 2023 |
Drugs and Companies using SELINEXOR ingredient
NCE-1 date: 04 July, 2023
Market Authorisation Date: 03 July, 2019
Treatment: Xpovio is indicated in combination with dexamethasone to treat relapsed or refractory multiple myeloma (refractory to at least an anti-cd38 mab, 2 proteasome inhibitors and 2 immunomodulatory agents) ...
Dosage: TABLET;ORAL
XPOVIO family patents
165. Xultophy 100/3.6 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
|
US9132239 (Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-242) | Aug 08, 2022 |
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN DEGLUDEC; LIRAGLUTIDE ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
XULTOPHY 100/3.6 family patents
166. Zecuity patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9327114 | TEVA BRANDED PHARM | User-activated self-contained co-packaged iontophoretic drug delivery system |
Oct, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jan 17, 2016 |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 17 January, 2013
Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof
Dosage: SYSTEM;IONTOPHORESIS
ZECUITY family patents
167. Zelboraf patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9447089 | HOFFMANN LA ROCHE | Compositions and uses thereof |
Jun, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-158) | Nov 06, 2024 |
| M(M-184) | Aug 31, 2019 |
| New Indication(I-757) | Nov 06, 2020 |
| Orphan Drug Exclusivity(ODE-13) | Aug 17, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 17, 2016 |
| Orphan Drug Exclusivity(ODE) | Aug 17, 2018 |
Drugs and Companies using VEMURAFENIB ingredient
NCE-1 date: 18 August, 2015
Market Authorisation Date: 17 August, 2011
Treatment: NA
Dosage: TABLET;ORAL
ZELBORAF family patents
168. Zerbaxa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8685957 | CUBIST PHARMS LLC | Tazobactam arginine compositions |
Sep, 2032
(8 years from now) | |
| US8476425 | CUBIST PHARMS LLC | Tazobactam arginine compositions |
Sep, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9724353 | CUBIST PHARMS LLC | Methods for treating intrapulmonary infections |
Sep, 2032
(8 years from now) | |
| US10028963 | CUBIST PHARMS LLC | Methods for treating intrapulmonary infections |
Sep, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| New Patient Population(NPP) | Apr 21, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Dec 19, 2024 |
Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient
NCE-1 date: 20 December, 2023
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of ventilator-associated bacterial pneumonia; Treatment of hospital-acquired bacterial pneumonia; Methods of treating bacterial illnesses
Dosage: POWDER;INTRAVENOUS
ZERBAXA family patents
169. Zerviate patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9254286 | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Jul, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 30, 2020 |
| Pediatric Exclusivity(PED) | Nov 30, 2020 |
Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 May, 2017
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
ZERVIATE family patents
170. Zolpimist patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8236285 | AYTU | Buccal, polar and non-polar spray containing zolpidem |
Aug, 2032
(8 years from now) | |
Drugs and Companies using ZOLPIDEM TARTRATE ingredient
Market Authorisation Date: 19 December, 2008
Treatment: Treatment of transient insomnia
Dosage: SPRAY, METERED;ORAL
ZOLPIMIST family patents
171. Zubsolv patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11433066 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US9439900 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US10946010 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US10874661 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US9259421 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US11020387 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US11020388 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US8940330 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-713) | Aug 10, 2018 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 October, 2016
Treatment: Use of zubsolv for treatment of opioid dependence
Dosage: TABLET;SUBLINGUAL
ZUBSOLV family patents
172. Zurampic patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8546436 | IRONWOOD PHARMS INC | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
Feb, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2020 |
Drugs and Companies using LESINURAD ingredient
NCE-1 date: 23 December, 2019
Market Authorisation Date: 22 December, 2015
Treatment: NA
Dosage: TABLET;ORAL
ZURAMPIC family patents
173. Zykadia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9309229 | NOVARTIS | Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
Jan, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8703787 | NOVARTIS | Methods of using ALK inhibitors |
Feb, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-145) | May 26, 2024 |
| M(M-199) | May 26, 2020 |
| New Chemical Entity Exclusivity(NCE) | Apr 29, 2019 |
| Orphan Drug Exclusivity(ODE) | May 26, 2024 |
| Orphan Drug Exclusivity(ODE-66) | Apr 29, 2021 |
Drugs and Companies using CERITINIB ingredient
NCE-1 date: 29 April, 2018
Market Authorisation Date: 29 April, 2014
Treatment: Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk)
Dosage: CAPSULE;ORAL
ZYKADIA family patents
List of large molecules
1. List of Tysabri large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9316641 | BIOGEN INC. | Assay for JC virus antibodies |
Jan, 2032
(7 years from now) | |
| US10308706 | BIOGEN INC. | Methods of preventing and removing trisulfide bonds |
Feb, 2032
(7 years from now) | |
| US10590454 | BIOGEN INC. | Methods of preventing and removing trisulfide bonds |
May, 2032
(8 years from now) | |
| US9790533 | BIOGEN INC. | Methods of preventing and removing trisulfide bonds |
May, 2032
(8 years from now) |
Ingredients: NATALIZUMAB
2. List of Eylea large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10828345 | REGENERON PHARMACEUTICALS, INC. | Use of a VEGF antagonist to treat angiogenic eye disorders |
Jan, 2032
(7 years from now) | |
| US10857205 | REGENERON PHARMACEUTICALS, INC. | Use of a VEGF antagonist to treat angiogenic eye disorders |
Jan, 2032
(7 years from now) | |
| US10888601 | REGENERON PHARMACEUTICALS, INC. | Use of a VEGF antagonist to treat angiogenic eye disorders |
Jan, 2032
(7 years from now) | |
| US10130681 | REGENERON PHARMACEUTICALS, INC. | Use of a VEGF antagonist to treat angiogenic eye disorders |
Jan, 2032
(7 years from now) | |
| US9669069 | REGENERON PHARMACEUTICALS, INC. | Use of a VEGF antagonist to treat angiogenic eye disorders |
Jan, 2032
(7 years from now) | |
| US11253572 | REGENERON PHARMACEUTICALS, INC. | Use of a VEGF antagonist to treat angiogenic eye disorders |
Jan, 2032
(7 years from now) | |
| US9254338 | REGENERON PHARMACEUTICALS, INC. | Use of a VEGF antagonist to treat angiogenic eye disorders |
May, 2032
(8 years from now) |
Ingredients: AFLIBERCEPT
3. List of Avastin large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9487809 | GENENTECH, INC. | Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase |
Jan, 2032
(7 years from now) | |
| US10513697 | GENENTECH, INC. | CO2 profile cultivation |
Sep, 2032
(8 years from now) |
Ingredients: BEVACIZUMAB
4. List of Humira large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8708968 | ABBVIE INC. | Removal of needle shields from syringes and automatic injection devices |
Jan, 2032
(7 years from now) | |
| US9339610 | ABBVIE INC. | Removal of needle shield from syringes and automatic injection devices |
Jan, 2032
(7 years from now) | |
| US9090688 | ABBVIE INC. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
Apr, 2032
(8 years from now) | |
| US9062106 | ABBVIE INC. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
Apr, 2032
(8 years from now) | |
| US9683033 | ABBVIE INC. | Cell culture methods to reduce acidic species |
Apr, 2032
(8 years from now) | |
| US9522953 | ABBVIE INC. | Low acidic species compositions and methods for producing and using the same |
Apr, 2032
(8 years from now) | |
| US9505834 | ABBVIE INC. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
Apr, 2032
(8 years from now) | |
| US9957318 | ABBVIE INC. | Protein purification methods to reduce acidic species |
Apr, 2032
(8 years from now) |
Ingredients: ADALIMUMAB
5. List of Aimovig large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9102731 | NA | Human CGRP receptor binding proteins |
May, 2032
(8 years from now) |
Ingredients: ERENUMAB-AOOE
6. List of Takhzyro large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8816055 | NA | Plasma kallikrein binding proteins |
Aug, 2032
(8 years from now) |
Ingredients: LANADELUMAB-FLYO
7. List of Crysvita large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US7883705 | NA | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
Nov, 2032
(8 years from now) |
Ingredients: BUROSUMAB-TWZA